Poster présenté par Th. Farge (Inserm U1037) au meeting de l’AACR dédié aux modèles PDX (USA, New Orleans, 11-14 février 2016)

Poster presented by C. Pensec (Biofortis) at “PROBIOTA Congress” Amsterdam, “Onco Week” Toulouse and “4th R&D Business collaboration forum Europe” London
02/02/2016
Poster presented by JF Mirjolet (Oncodesign) at the Annual AACR congress (USA, New Orleans, 16-20 avril 2016)
16/04/2016

Poster présenté par Th. Farge (Inserm U1037) au meeting de l’AACR dédié aux modèles PDX (USA, New Orleans, 11-14 février 2016)

Studying cytarabine resistance through PDX models
in acute myeloid leukemia

Introduction

The major therapeutic barrier in acute myeloid leukemia (AML) is chemotherapy resistance. AML cells resistant to conventional chemotherapy targeting DNA synthesis are thought to be enriched in quiescent leukemic stem cells (LSCs). In order to better understand chemotherapy resistance in AML, we analyzed the response to cytarabine (AraC) through patient-derived xenograft (PDX) models with 20 primary AML patient specimens from two clinical sites and in the context of a French “Innovative models initiative” (IMODI) program.
 
 
Share this